Istem Medikal

Dexell - Model VUR - Injectable Implant for the Treatment of Vesicoureteral Reflux

FromIstem Medikal

SHARE

Vesicoureteral reflux (VUR) is the retrograde passage of urine from the bladder into the upper urinary tract. It is the most common urological diagnosis in children, occuring in approximately 1 % of newborns and as high as 30 to 45% in children with UTI. Additionally, there is a high association between VUR, UTI, hypertension and renal damage.

Most popular related searches

hyaluronic acid

antibiotic therapy

antibiotic resistant

injectable implant

collagen synthesis

antibiotic resistance

Conventional Low Dose Antibiotic Therapy

Extended treatment time
Patient/parent non-compliance
Risk of antibiotic resistance
Break through UTI

Surgical Ureter Reimplantation

lnvasive
Reimplantation of ureter into bladder
High success rate

Endoscopic Dextranomer/Hyaluronic Acid Injection

Surgical injection of dextranomer/hyaluronic acid
Minimally invasive
lmmediate correction of VUR
High success rate

Non Immunogenic
Biocompatible
Non allergic
Biodegradable by time
Long lasting
No migration
No rigid

DEXELL ®

DEXELL ® consists of positively charged DEAE dextranomer microspheres (active ingredient) suspended in a cross linked hyaluronic acid gel solution (transporter). Both the dextranomer micro-particles and hyaluronate gel are biocompatible, non-immunogenic and biodegradable.

DEXELL ®

After initial injection the dextranomer microspheres and hyaluronate gel provide volume. The dextranomer microspheres stimulate collagen synthesis and fibroblast ingrowth into the degrading hyaluronic matrix, consolidating the implant within the bladder wall through endogenous tissue augmentation.

DEXELL ® is suitable to be used with a cystoscopic injection needle in all injection methods e.g. STING and HIT.